Home > Oncology > ESMO 2021 > Genitourinary Cancer > Both men with high-risk non-metastatic prostate cancer and men with metastatic prostate cancer benefit from intensified hormone treatment

Both men with high-risk non-metastatic prostate cancer and men with metastatic prostate cancer benefit from intensified hormone treatment

Conference
ESMO 2021
Trial
Phase 3, PEACE-1, STAMPEDE, ARCHES
Three trials – PEACE-1, two combined STAMPEDE cohorts, and ARCHES – highlighted the benefits of treatment intensification with androgen receptor signalling inhibitors in patients with hormone-sensitive prostate cancer (HSPC). Although treatment with androgen deprivation therapy (ADT) and local radiotherapy has improved outcome of patients with high-risk non-metastatic (M0) prostate cancer, post-treatment failure rates are high. In patients with metastatic prostate cancer, addition of abiraterone-acetate/prednisone (AAP) to ADT has proven to increase overall survival (OS). However, due to low numbers of events, no statistically significant benefit of addition of AAP to ADT was shown in patients with M0 prostate cancer [1]. To power the endpoint of metastases-free survival (MFS) in M0 patients, the STAMPEDE investigators combined M0 patients from 2 comparisons in the STAMPEDE platform protocol (


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on